FluoroPharma To Present Phase I Study Results Of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer

Main Category: Cardiovascular / Cardiology
Also Included In: MRI / PET / Ultrasound;  Clinical Trials / Drug Trials;  Conferences
Article Date: 16 Jun 2009 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.

The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School, at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT).

BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually.

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Source: FluoroPharma Inc